Table 1.

Targeted therapy for EGFR, ALK, and RET

Inhibitor	Target	Types of cancer
Gilotrif(Afatinib) [32]	EGFR	NSCLC, pancreatic cancer, colon cancer, head and neck cancer
Iressa (Gefitinib) [33]
Tarceva (Erlotinib) [34, 35]
Erbitux (Cetuximab) [36, 37]
Vectibix (Panitumumab) [38]
Portrazza (Necitumumab) [39]		Squamous cell lung cancer
Tagrisso (Osimertinib) [40]	EGFR (T790M)	Cancers failed with Gilotrif, Iressa or Tarceva
Xalkori (Crizotinib) [43]	ALK	Lung cancer, metastatic NSCLC with ROS1 mutation
AP26113 (Brigatinib) [44]	ALK, EGFR (T790M)	NSCLC
Alecensa (Alectinib) [41, 42]	ALK	Metastatic tumor in the brain, central nervous system
Zykadia (Ceritinib) [45, 46]	ALK	Metastatic tumor in the brain, central nervous system, NSCLC
Cometriq (Cabozantinib) [47, 48]	RET	Thyroid cancer, prostate cancer, melanoma
Caprelsa (Vandetanib) [49]